Literature DB >> 9039244

Diffuse lung disease: product of genetic susceptibility and environmental encounters.

P A Lympany1, R M du Bois.   

Abstract

Diffuse (interstitial) lung disease comprises a wide variety of conditions, individually relatively uncommon but collectively being found in approximately 50 per 100,000 population. Some of these diseases are of known aetiology but others are not. It has been suggested that the environment is a major contributory factor in this group of diseases. However, since not all individuals exposed to a common environment develop interstitial diseases, it can be hypothesised that there is a genetic predisposition to their development. These diseases cause major morbidity and mortality due to lung injury and fibrosis. It follows that, if individuals who are genetically predisposed to develop diseases characterised by lung injury and fibrosis can be identified, then management strategies can be designed which will attempt to identify and treat early disease and, in the longer term, to develop targeted genetic interventional approaches to treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039244      PMCID: PMC1758416          DOI: 10.1136/thx.52.1.92

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

Review 1.  The geneticist's approach to complex disease.

Authors:  S Ghosh; F S Collins
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

2.  Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis.

Authors:  D C Briggs; R W Vaughan; K I Welsh; A Myers; R M duBois; C M Black
Journal:  Lancet       Date:  1991-09-14       Impact factor: 79.321

Review 3.  Genetics of scleroderma.

Authors:  C M Black; K I Welsh
Journal:  Clin Dermatol       Date:  1994 Jul-Sep       Impact factor: 3.541

4.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

5.  HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.

Authors:  L Richeldi; R Sorrentino; C Saltini
Journal:  Science       Date:  1993-10-08       Impact factor: 47.728

6.  Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3.

Authors:  J Grunewald; C H Janson; A Eklund; M Ohrn; O Olerup; U Persson; H Wigzell
Journal:  Eur J Immunol       Date:  1992-01       Impact factor: 5.532

Review 7.  Autoantibodies in systemic sclerosis.

Authors:  D Vázquez-Abad; N F Rothfield
Journal:  Int Rev Immunol       Date:  1995       Impact factor: 5.311

8.  "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries.

Authors:  M Martinetti; C Tinelli; V Kolek; M Cuccia; L Salvaneschi; L Pasturenzi; G Semenzato; A Cipriani; A Bartova; M Luisetti
Journal:  Am J Respir Crit Care Med       Date:  1995-08       Impact factor: 21.405

  8 in total
  4 in total

Review 1.  In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many?

Authors:  M Turner-Warwick
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

2.  Cardiac Effect of Interstitial Lung Disease Correlated with Spirometry and Six Minute Walk Test.

Authors:  Mitali Bharat Agrawal; Nilkanth Tukaram Awad
Journal:  J Clin Diagn Res       Date:  2017-02-01

3.  Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis.

Authors:  S Pabst; G Baumgarten; A Stremmel; M Lennarz; P Knüfermann; A Gillissen; H Vetter; C Grohé
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

Review 4.  New ideas on the pathophysiology and treatment of lung disease.

Authors:  D F Rogers; G J Laurent
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.